1. Home
  2. IRON vs QURE Comparison

IRON vs QURE Comparison

Compare IRON & QURE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Disc Medicine Inc.

IRON

Disc Medicine Inc.

HOLD

Current Price

$80.94

Market Cap

3.1B

Sector

Health Care

ML Signal

HOLD

Logo uniQure N.V.

QURE

uniQure N.V.

HOLD

Current Price

$47.46

Market Cap

3.2B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
IRON
QURE
Founded
2017
1998
Country
United States
Netherlands
Employees
N/A
248
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
3.1B
3.2B
IPO Year
2020
2013

Fundamental Metrics

Financial Performance
Metric
IRON
QURE
Price
$80.94
$47.46
Analyst Decision
Strong Buy
Buy
Analyst Count
11
14
Target Price
$103.18
$45.00
AVG Volume (30 Days)
320.6K
1.3M
Earning Date
05-07-2026
05-05-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
29.67
EPS
N/A
N/A
Revenue
N/A
$13,107,000.00
Revenue This Year
N/A
$126.12
Revenue Next Year
$283.52
$200.43
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$40.00
$8.73
52 Week High
$99.50
$71.50

Technical Indicators

Market Signals
Indicator
IRON
QURE
Relative Strength Index (RSI) 62.13 60.09
Support Level $70.73 $39.50
Resistance Level $82.74 $50.47
Average True Range (ATR) 2.94 1.95
MACD 0.05 0.07
Stochastic Oscillator 87.72 63.40

Price Performance

Historical Comparison
IRON
QURE

About IRON Disc Medicine Inc.

Disc Medicine Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for hematologic diseases. It aims to modify fundamental biological pathways associated with the formation and function of red blood cells, specifically heme biosynthesis and iron homeostasis. Its pipeline includes bitopertin for erythropoietic porphyrias (EPs), including erythropoietic protoporphyria (EPP), X-linked protoporphyria (XLP), and Diamond-Blackfan Anemia (DBA); DISC-0974 for the treatment of anemia of myelofibrosis (MF) and anemia of chronic kidney disease (CKD); and DISC-3405 for the treatment of polycythemia vera (PV) and other hematologic disorders. In addition, the Company's preclinical programs include DISC-0998.

About QURE uniQure N.V.

uniQure NV is a gene therapy company. It develops treatments and platforms for patients suffering from genetic and other devastating diseases. Its products and services are focused on hemophilia, Huntington's disease, and cardiovascular diseases. The company is focused on the development of the pipeline of gene therapies with the collaboration of Bristol Myers Squibb for cardiovascular diseases. Its program and pipeline involves: Huntington's Disease, Temporal Lobe Epilepsy (TLE), Fabry Disease, ALS (SOD1), Hemophilia B, Clinical Trials, and Research Programs.

Share on Social Networks: